NCT04203160 2025-12-31
Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)
University of Michigan Rogel Cancer Center
Phase 1/2 Terminated
Clinical Trials
9 trialsNCT03374852 2025-04-29
CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer
Thomas Jefferson University
Phase 2 Withdrawn
NCT03699319 2025-01-23
CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer
Case Comprehensive Cancer Center
Phase 1/2 Completed
NCT02232152 2023-08-07
CPI-613 and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery
Wake Forest University Health Sciences
Phase 1 Completed
NCT01835041 2023-07-12
CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer
Wake Forest University Health Sciences
Phase 1 Completed
NCT05733000 2023-03-10
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
Northwestern University
Phase 2 Recruiting
NCT01766219 2019-05-15
CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery
Wake Forest University Health Sciences
Phase 1/2 Completed
NCT01839981 2018-12-27
CPI-613 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
Wake Forest University Health Sciences
Phase 1 Completed
NCT03435289 2018-02-19
A Study of CPI-613 With Gemcitabine and Nab-paclitaxel for Patients With Advanced or Metastatic Pancreatic Cancer
Atlantic Health System
Phase 1 Unknown